For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
15
views
80
references
 Top references
cited by
9
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      532
      similar
       All similar

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Endocrine toxicity of cancer immunotherapy: clinical challenges

      review-article
      Author(s): 1 , 1
      Publication date (Electronic):
      Journal: Endocrine Connections
      Publisher: Bioscientifica Ltd
      Keywords: checkpoint inhibitor, cancer, thyroiditis, hypophysitis, diabetes

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune checkpoint inhibitors are now widely used in the treatment of multiple cancers. The major toxicities of these treatments are termed immune-related adverse events and endocrine dysfunction is common. Thyroid disease, hypopituitarism and a form of diabetes resembling type 1 diabetes are now all well described, with different patterns emerging with different checkpoint inhibitors. We review the presentation and management of the common endocrine immune-related adverse events, and discuss a number of recent advances in the understanding of these important, potentially life threatening toxicities. We also discuss some remaining dilemmas in management.

          Related collections

          Most cited references80

          • Record: found
          • Abstract: not found
          • Article: not found
          Is Open Access

          Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

          J.B.A.G. Haanen, F Carbonnel, C. Robert … (2017)
          Article 0 comments Cited 650 times – based on 0 reviews     Review now
            • Record: found
            • Abstract: found
            • Article: not found

            Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

            Frank Hodi, Vanna Chiarion-Sileni, Rene Gonzalez … (2018)
            Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study.
            Article 0 comments Cited 478 times – based on 0 reviews     Review now
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Cancer immunotherapy: the beginning of the end of cancer?

              Sofia Farkona, Eleftherios P. Diamandis, Ivan M Blasutig (2016)
              These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.
              Article 0 comments Cited 466 times – based on 0 reviews     Review now
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Endocr Connect
                Journal ID (iso-abbrev): Endocr Connect
                Journal ID (hwp): EC
                Title: Endocrine Connections
                Publisher: Bioscientifica Ltd (Bristol )
                ISSN (Electronic): 2049-3614
                Publication date Collection: March 2021
                Publication date (Electronic): 04 February 2021
                Volume: 10
                Issue: 3
                Pages: R116-R124
                Affiliations
                [1 ]Department of Endocrinology , Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
                Author notes
                Correspondence should be addressed to D L Morganstein: d.morganstein@ 123456imperial.ac.uk
                Article
                Publisher ID: EC-20-0489
                DOI: 10.1530/EC-20-0489
                PMC ID: 8052567
                PubMed ID: 33544091
                SO-VID: 8a11ac50-c316-45d2-9d24-5dc6740127d8
                Copyright © © 2021 The authors
                License:

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                Date received : 17 January 2021
                Date accepted : 04 February 2021
                Categories
                Subject: Review

                Keywords: checkpoint inhibitor,cancer,thyroiditis,hypophysitis,diabetes
                Data availability:
                Keywords: checkpoint inhibitor, cancer, thyroiditis, hypophysitis, diabetes

                Comments

                Comment on this article

                Related Documents Log
                scite_

                Similar content532

                See all similar

                Cited by9

                See all cited by

                Most referenced authors1,063

                See all reference authors